Recently, Bensch et al. impressively demonstrated the potential of such a theranostic approach by correlating the accumulation of a radiolabeled antibody against programmed death ligand 1 (PD-L1) in tumors with the therapeutic response to immune checkpoint blockade and showed the superiority of this method to standard histological evaluation of PD-L1-expression in the initial tumor biopsy 38. The gene discussed is CD274; the disease is neoplasm.